Publications by authors named "Danielle Stonely"
Background: Current guidelines recommend simultaneous initiation of multidrug guideline-directed medical therapy classes for heart failure with reduced ejection fraction.
Objectives: The purpose of this study was to evaluate county-level variation in use of triple guideline-directed medical therapy, defined as simultaneous prescription fills for beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists, in heart failure with reduced ejection fraction.
Methods: We conducted a cohort study using Medicare Fee-for-Service claims data (parts A, B, and D between 2013 and 2019).
Background: In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.
Methods: Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination.
Article Synopsis
- - The study focused on the effectiveness of Ziv-aflibercept, a drug that inhibits vascular endothelial growth factor (VEGF), in patients with advanced neuroendocrine tumors (NETs).
- - In a phase II trial with 19 patients, the results showed a median progression-free survival of 11.8 months and a median overall survival of 36.4 months, but high rates of hypertension (95%) were observed.
- - The findings suggest that while Ziv-aflibercept has similar efficacy to other VEGF inhibitors in treating NETs, its significant side effects may limit further research on its use.